Kollender Richard S

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · derivative · entry 4

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,827 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · derivative · entry 3

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,681 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · nonDerivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,826

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415666-26-000005 · wk-form4_1779837903.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001415666-26-000005 · wk-form4_1779837903.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,318

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001380106-25-000131 · wk-form4_1748391037.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,650

Underlying: Class A Common Stock · 28,650 shares

Expires 2035-05-21

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001380106-25-000131 · wk-form4_1748391037.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,018

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001380106-24-000175 · wk-form4_1723062874.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,718

F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.7690 to $0.7852 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001380106-24-000144 · wk-form4_1716937427.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,650

Underlying: Class A Common Stock · 28,650 shares

Expires 2034-05-22

F3 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001380106-24-000144 · wk-form4_1716937427.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,718

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

F2 · balance_after: Includes 17,418 shares of Class A common stock received in pro rata distributions by Quaker Bioventures II, L.P. to its limited partners for no additional consideration, which were exempt from reporting.

SEC source: 0001380106-23-000080 · wf-form4_168332420163997.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2033-05-03

F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001127602-22-017268 · form4.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Class A Common Stock · 12,500 shares

Expires 2032-05-22

F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001179110-21-009284 · edgar.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 544,918 shares

Expires not disclosed

F2 · derivative.exercise_price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · derivative.exercise_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · derivative.expiration_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

SEC source: 0001179110-21-009284 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

F1 · price: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

SEC source: 0001179110-21-009228 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,229

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001104659-21-115207 · tm2127517-1_4seq1.xml · derivative · entry 4

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 12,903 shares

Expires 2028-01-17

F2 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is an executive manager of Quaker Bioventures Capital II, LLC, the general partner of Quaker Bioventures Capital II, L.P, the general partner of Quaker Bioventures II, LP, and may be deemed to beneficially hold the shares but disclaims beneficial ownership thereof, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-21-115207 · tm2127517-1_4seq1.xml · derivative · entry 3

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 12,903 shares

Expires 2027-12-06

F2 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is an executive manager of Quaker Bioventures Capital II, LLC, the general partner of Quaker Bioventures Capital II, L.P, the general partner of Quaker Bioventures II, LP, and may be deemed to beneficially hold the shares but disclaims beneficial ownership thereof, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-21-115207 · tm2127517-1_4seq1.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 82,010 shares

Expires 2027-07-24

F2 · derivative.exercise_date: Immediately exercisable.

F1 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is an executive manager of Quaker Bioventures Capital II, LLC, the general partner of Quaker Bioventures Capital II, L.P, the general partner of Quaker Bioventures II, LP, and may be deemed to beneficially hold the shares but disclaims beneficial ownership thereof, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-21-115207 · tm2127517-1_4seq1.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 1,481,009

F1 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is an executive manager of Quaker Bioventures Capital II, LLC, the general partner of Quaker Bioventures Capital II, L.P, the general partner of Quaker Bioventures II, LP, and may be deemed to beneficially hold the shares but disclaims beneficial ownership thereof, except to the extent of any pecuniary interest therein.

SEC source: 0001179110-21-008673 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,020

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 10

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 12,903

Underlying: Class A Common Stock · 12,903 shares

Expires 2027-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F4 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 9

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Series B1 Preferred Stock · 64,516 shares

Expires 2027-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F4 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 8

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 12,903

Underlying: Class A Common Stock · 12,903 shares

Expires 2028-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F4 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 7

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Series B1 Preferred Stock · 64,516 shares

Expires 2028-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F4 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 6

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 82,010

Underlying: Class A Common Stock · 82,010 shares

Expires 2027-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F4 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 5

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Series A1 Preferred Stock · 410,051 shares

Expires 2027-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F3 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 4

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 164,145 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 3

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 226,180 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 0

Underlying: Class A Common Stock · 924,759 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-094111 · tm2122156-21_4seq1.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Quaker Bioventures II, L.P.

Disclosed balance after: 1,373,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares.

SEC source: 0001104659-21-092759 · tm2122156-15_4seq1.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001179110-21-005554 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,108

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001179110-21-002971 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,500

F1 · shares: Represents a grant of restricted stock units, which vest in full on March 3, 2023, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The grant was made in connection with Mr. Kollender's appointment to the position of President and Chief Financial Officer.

SEC source: 0001179110-21-000426 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,500

F1 · shares: Represents a grant of restricted stock units, which vest in full on January 7, 2023, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001179110-20-000877 · edgar.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-01-27

F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning April 27, 2020, provided the Reporting Person is employed by the Issuer on each vesting date.

SEC source: 0001179110-19-010061 · edgar.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2029-09-03

F3 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning December 3, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.

SEC source: 0001179110-19-010061 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: Represents a grant of restricted stock units, which vest in full on September 3, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: All of these ordinary shares are in the form of restricted stock units.

SEC source: 0001179110-19-006151 · edgar.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: Represents a grant of restricted stock units, which vest in full on May 15, 2020, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001179110-18-006949 · edgar.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-05-15